- Global Pharma News & Resources

Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference

BOULDER, Colo., Aug. 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq : ARRY ) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Wells Fargo Securities 2018 Healthcare Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   


Wells Fargo Securities 2018 Healthcare Conference


Ron Squarer, Chief Executive Officer, Array BioPharma


Thursday, September 6, 2018


3:05 p.m. Eastern Time


About Array BioPharma

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI┬« (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including selumetinib (partnered with AstraZeneca), larotrectinib (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797 (being developed by Yarra Therapeutics, a wholly-owned subsidiary of Array), all of which are currently in registration trials. Ganovo┬« (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit or follow @arraybiopharma on Twitter and LinkedIn.


Andrea N. Flynn, Ph.D.

Senior Director, Investor Relations & Corporate Communications

(303) 381-6600

Editor Details

Related Links

Last Updated: 31-Aug-2018